Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATXS

ATXS - Astria Therapeutics, Inc. Stock Price, Fair Value and News

13.24USD-0.71 (-5.09%)Delayed as of 21 Feb 2024, 12:03 pm ET
Watchlist

Market Summary

USD13.24-0.71
Delayedas of 21 Feb 2024, 12:03 pm
-5.09%

ATXS Alerts

  • 1 major insider buys and 1 major insider sales recently.

ATXS Stock Price

View Fullscreen

ATXS RSI Chart

ATXS Valuation

Market Cap

506.3M

Price/Earnings (Trailing)

-9.25

Price/Free Cashflow

-10.35

ATXS Price/Earnings (Trailing)

ATXS Profitability

Return on Equity

-29.67%

Return on Assets

-28.24%

Free Cashflow Yield

-9.66%

ATXS Fundamentals

ATXS Earnings

Earnings (TTM)

-54.7M

Earnings Growth (Yr)

-47.76%

Earnings Growth (Qtr)

-41.07%

Breaking Down ATXS Revenue

52 Week Range

6.7315.00
(Low)(High)

Last 7 days

-6.9%

Last 30 days

99.9%

Last 90 days

216.1%

Trailing 12 Months

-5.8%

How does ATXS drawdown profile look like?

ATXS Financial Health

Current Ratio

20.41

ATXS Investor Care

Shares Dilution (1Y)

115.72%

Diluted EPS (TTM)

-2.12

Tracking the Latest Insider Buys and Sells of Astria Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
perceptive advisors llc
bought
29,999,500
12.09
2,481,350
-
Jan 29, 2024
morabito christopher
sold
-102,552
11.147
-9,200
chief medical officer
Jan 29, 2024
morabito christopher
acquired
35,604
3.87
9,200
chief medical officer
Jan 26, 2024
morabito christopher
sold
-8,812
11.015
-800
chief medical officer
Jan 26, 2024
morabito christopher
acquired
3,096
3.87
800
chief medical officer
Dec 21, 2023
perceptive advisors llc
bought
4,588,000
6.2
740,000
-
Oct 16, 2023
perceptive advisors llc
bought
7,000,000
6.514
1,074,610
-
Dec 19, 2022
perceptive advisors llc
bought
10,000,000
11.01
908,265
-
Dec 28, 2021
komjathy andrew
gifted
-
-
-90.00
chief commercial officer
Nov 19, 2021
komjathy andrew
bought
669
6.695
100
chief commercial officer

1–10 of 12

Which funds bought or sold ATXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
added
98.27
4,509,520
8,840,790
1.42%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
307,792
307,792
-%
Feb 15, 2024
Legal & General Group Plc
added
34.41
7,412
26,819
-%
Feb 15, 2024
BARCLAYS PLC
added
487
317,000
379,000
-%
Feb 14, 2024
Saturn V Capital Management LP
reduced
-18.74
-1,486,140
7,608,290
2.91%
Feb 14, 2024
Rosalind Advisors, Inc.
new
-
8,668,480
8,668,480
7.14%
Feb 14, 2024
Schonfeld Strategic Advisors LLC
reduced
-24.00
-77,102
277,248
-%
Feb 14, 2024
Altium Capital Management LP
reduced
-45.81
-4,442,880
5,606,400
3.81%
Feb 14, 2024
DEUTSCHE BANK AG\
unchanged
-
3,656
127,634
-%
Feb 14, 2024
Ikarian Capital, LLC
unchanged
-
82,457
2,878,520
0.27%

1–10 of 45

Are Funds Buying or Selling ATXS?

Are funds buying ATXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATXS
No. of Funds

Unveiling Astria Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2024
fairmount funds management llc
9.9%
3,633,965
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
0.00%
0
SC 13G/A
Feb 13, 2024
vivo opportunity, llc
4.5%
2,482,727
SC 13G/A
Feb 13, 2024
vanguard group inc
5.66%
2,055,707
SC 13G
Feb 12, 2024
ra capital management, l.p.
8.1%
4,413,150
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 05, 2024
perceptive advisors llc
11.9%
6,485,420
SC 13D/A
Jan 29, 2024
blackrock inc.
6.0%
2,184,558
SC 13G
Jan 16, 2024
tcg crossover gp ii, llc
9.9%
4,368,928
SC 13G

Recent SEC filings of Astria Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
4
Insider Trading

Peers (Alternatives to Astria Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Astria Therapeutics, Inc. News

Latest updates
MarketBeat13 Feb 202405:35 pm

Astria Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-6.4%19420721823112010511512813514114947.0057.0057.0059.0042.0044.0049.0054.0039.0045.00
  Current Assets-6.3%19120421522811810411412713514014846.0056.0056.0057.0039.0043.0047.0053.0039.0045.00
    Cash Equivalents-10.6%12013420221.0046.0030.0047.0087.0013214014725.0053.0052.0013.0010.0018.0010.0012.0015.0020.00
  Net PPE-------------------0.000.000.00
Liabilities41.1%9.007.007.009.007.006.005.005.005.004.009.007.008.006.005.006.006.005.005.004.004.00
  Current Liabilities42.2%9.007.007.009.006.005.005.005.005.004.004.006.007.006.005.005.006.005.004.004.004.00
Shareholder's Equity-7.9%18420021122111399.0011012213013733041.0049.0029228536.0038.0025425335.0041.00
  Retained Earnings-3.3%-549-531-518-507-494-482-471-455-446-438-430-260-251-241-231-223-216-210-203-197-191
  Additional Paid-In Capital0.3%638636635633511486484482480475330302301292285259255254253232232
Shares Outstanding0.1%28.0028.0028.0028.0014.0013.0013.0013.0013.005.004.003.00---------
Float------26.00---130---101---73.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-33.3%-14,258-10,696-13,253-10,664-10,249-10,061-12,559-6,286-7,749-7,400-8,716-8,061-9,969-7,466-6,989-7,770-6,474-5,738-6,587-5,269-5,775
  Share Based Compensation27.3%1,6941,3311,2201,0731,1551,1171,2099721,0101,014366305375--285378441408431416
Cashflow From Investing100.0%-4.00-57,920194,992-135,1801,950-6,800-27,099-39,000--26,445-20,0102,00039,742-15,432-3,50413,6513,509-17,7381,094-23,007
Cashflow From Financing-59.7%11027337.00120,397---17.006.00-104,26131.008,9406,26525,6243,77297319220,683-407-1,273

ATXS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 13,338$ 7,698$ 30,460$ 24,673
General and administrative6,8984,68818,37114,540
Total operating expenses20,23612,38648,83139,213
Loss from operations(20,236)(12,386)(48,831)(39,213)
Other income (expense):    
Interest and investment income2,5274377,404706
Other expense, net(18)(48)(54)(64)
Total other income, net2,5093897,350642
Net loss$ (17,727)$ (11,997)$ (41,481)$ (38,571)
Net loss per share attributable to common shareholders - basic$ (0.63)$ (0.87)$ (1.48)$ (2.91)
Net loss per share attributable to common shareholders - diluted$ (0.63)$ (0.87)$ (1.48)$ (2.91)
Weighted-average common shares outstanding used in net loss per share - basic28,040,17313,742,38528,002,66313,261,422
Weighted-average common shares outstanding used in net loss per share - diluted28,040,17313,742,38528,002,66313,261,422

ATXS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 119,806$ 20,525
Short-term investments69,000205,912
Prepaid expenses and other current assets2,6601,253
Total current assets191,466227,690
Right-of-use asset514948
Other assets1,8811,995
Total assets193,861230,633
Current liabilities:  
Accounts payable1,138788
Accrued expenses7,7567,690
Current portion of operating lease liabilities488582
Total current liabilities9,3829,060
Long term portion of operating lease liabilities 357
Total liabilities9,3829,417
Commitments (Note 6)
Stockholders' equity:  
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 28,042,296 and 27,501,340 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively2828
Additional paid-in capital638,251632,512
Accumulated other comprehensive loss (79)
Accumulated deficit(549,124)(507,643)
Total stockholders' equity184,479221,216
Total liabilities and stockholders' equity193,861230,633
Preferred stock  
Stockholders' equity:  
Preferred stock
Series X redeemable convertible preferred stock  
Stockholders' equity:  
Preferred stock$ 95,324$ 96,398
ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
 CEO
 WEBSITEwww.astriatx.com
 EMPLOYEES45

Astria Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Astria Therapeutics, Inc.? What does ATXS stand for in stocks?

ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Astria Therapeutics, Inc. (ATXS)?

As of Tue Feb 20 2024, market cap of Astria Therapeutics, Inc. is 506.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers. The fair value of Astria Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Astria Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Astria Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ATXS is over valued or under valued. Whether Astria Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Astria Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXS.